Marketing-Börse PLUS - Fachbeiträge zu Marketing und Digitalisierung
print logo

Tardive Dyskinesia Treatment Market

Global Tardive Dyskinesia Treatment Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2024
pbi | 01.05.2018

Global Tardive Dyskinesia Treatment Market :Tardive dyskinesia is a movement disorder which develops with long duration compliance to antipsychotic drugs. This is characterised primarily by random movements of tongue, jaws, lips and different muscles sometimes even with fingers, toes and legs. In sever conditions of tardive dyskinesia patients may experience heaving breathing associated with trunk or hips or muscles swaying movements. It is a long-term cause of neuroleptic drugs which are more often prescribed for certain mental, neurological or GI disorders.


Growing prevalence of patients suffering from various neurological disorders is the major factor driving the market growth of TD treatment. For example, In 2017 April, Neurocrine Biosciences has published a report which stated that about 5lakhs people are suffering from TD in U.S. Tardive dyskinesia treatment market is anticipated to grow significantly during the forecast period owing to rise in geriatric population, busy and tense lifestyle, growing prescription of anti-psychotic drugs etc. The factors which are hampering the growth TD market is approval process of new treatment approaches by respective governments, delayed diagnosis of the disease and lack of awareness regarding the disease.

A sample of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/global-tardive-dyskinesia-treatment-market/#ulp-4H8Z4LpNMLEuOnnx


The tardive dyskinesia treatment market is classified on the basis of drug class, infection type distribution channel, and geography.

Based on drug class, the tardive dyskinesia treatment market is segmented into the following

• Beta blockers
• Vitamin E systemic
• VMAT2 inhibitors (vesicular monoamine transporter-2 inhibitors)
• Dopaminergic agents
• Benzodiazepines

Based on route of administration, the tardive dyskinesia treatment market is segmented into the following

• Oral
• Parenteral


Based on distribution channel, the tardive dyskinesia treatment market is segmented into the following

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

To view TOC of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/global-tardive-dyskinesia-treatment-market/#ulp-c654SbFYO64MsOhu


A variety of medicines are used to treat tardive dyskinesia such as clonidine etc. Botox injections can be given for minor TD. Vitamin B6, vitamin E and branched chain amino acids are helpful in minimizing the symptoms of tardive dyskinesia. Benzodiazepines therapy is the most effective therapy for tardive dyskinesia. However, the development of tolerance is restraining its growth in the market. Teva’s AUSTEDO was approved for the treatment of chorea associated with tardive dyskinesia. Austedo is likely to create competition for INGREZZA of Neurocrine Biosciences.

Need more information about this report @
https://www.precisionbusinessinsights.com/market-reports/global-tardive-dyskinesia-treatment-market/#ulp-14mlyhjMGhVjZqa3



On the basis of Geographical regions, Global tardive dyskinesia treatment market is classified as into five key regions as Europe, Asia- Pacific, North America, Middle East & Africa and Latin America. North America is the dominating market in tardive dyskinesia owing to the development of new drugs, growing prevalence of tardive dyskinesia, rising investments on R&D investments. Europe and Asia Pacific are also expected to have significant growth rate due to the growing investments, rising awareness and rise in disposable income of the emerging countries.

Some of the players in global tardive dyskinesia treatment market are Biogen (U.S), Teva Pharmaceutical Industries Ltd. (Israel), GlaxoSmithKline Plc.(U.K), Johnson & Johnson Services, Inc.(U.S), Pfizer Inc.(U.S), Neurocrine Biosciences, Inc.(U.S), Novartis AG(Switzerland), AstraZeneca (U.K), Bayer AG (Germany) and Sanofi (France).

Get access to full summary @
https://www.precisionbusinessinsights.com/market-reports/global-tardive-dyskinesia-treatment-market/


About Precision Business Insights

Precision Business Insights is one of the leading market research and business consulting firm, the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised which follow a holistic approach to solve needs of market research services based on our client needs.

Precision Business Insights mission is to provide high-quality market research reports and generate key insights to our clients. PBI’s approachable strategies are to help clients to make key decisions for business growth.

Precision Business Insights vision is to become most valued partner to fortune 500 companies by providing agile, accurate, and actionable market insights

Contact to Precision Business Insights,

Kemp House,

152 – 160 City Road,

London EC1V 2NX

Email: sales@precisionbusinessinsights.com

Toll Free (US): +1-866-598-1553
Website @ https://www.precisionbusinessinsights.com

Img of pbi
About the tenderer: pbi

Precision Business Insights is one of the leading market research and business consulting firm,